Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Core Insights - Plus Therapeutics presented new data on its lead drug REYOBIQ™ at the Nuclear Medicine and Neurooncology Conference, highlighting its potential in treating Leptomeningeal Metastases (LM) [1][2] Group 1: REYOBIQ™ Data Presentation - The data indicates safety and clinical benefits of REYOBIQ in patients with LM, with multiple doses administered under compassionate use contributing to long-term survival [2] - The study titled "Rhenium Obisbemeda (REYOBIQ) in Leptomeningeal Metastases" provides additional insights from the completed Phase 1 ReSPECT-LM dose escalation trial [2] Group 2: Leptomeningeal Metastases Overview - LM is a rare but severe complication of cancer, affecting approximately 5% of cancer patients, with a notably low 1-year survival rate of 7% and a 2-year survival rate of 3% [4] - The incidence of LM is increasing, partly due to longer cancer patient lifespans and the ineffectiveness of standard chemotherapies in reaching sufficient concentrations in the cerebrospinal fluid [4] Group 3: REYOBIQ™ Mechanism and Efficacy - REYOBIQ™ is designed to deliver targeted high-dose radiation to CNS tumors, potentially improving outcomes compared to existing therapies [5] - The study reported a dose-dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space, reaching 253 Gy in Cohort 5 [6] - Clinical benefit rates were high, with 76% of patients showing complete response, partial response, or stable disease, and 87% demonstrating clinical response based on physician evaluation [6] Group 4: Clinical Trials and Funding - REYOBIQ™ is being evaluated in clinical trials for recurrent glioblastoma and leptomeningeal metastases, with funding support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [7]